Tagrisso 80mg is a kinase inhibitor, it is an oral, comes under third generation drug Tagrisso 80mg is an irreversible epidermal growth factor receptor tyrosine kinase inhibitor Tagrisso 80mg selectively prohibits both EGFR-TKI sensitizing and EFGR T790M resistance mutations Tagrisso 80mg is first line therapy in patients with EGFR mutated non-small cell lung cancer



30 tablets


First line indication is;
Respiratory carcinoma
Thoracic carcinoma
Tagrisso 80mg is mainly indicated for;
Patient with advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions as detected by FDA
• First line treatment of EGFR mutation positive metastatic non small cell lung cancer
• Previously treated EGFR T790M mutation positive metastatic non small cell lung cancer

Mechanism of action

Tagrisso 80mg is classified as tyrosine kinase inhibitor of epidermal growth factor receptor which is present on the surface of tumor cells
Tagrisso 80mg is non reversibly merge with mutant form of EGFR at 9 folds than wild type
Prohibits EGFR sensitizing mutations exon 19 Del and L858R
Leads to prohibits mutated EGFR with T790M resistance mutation
Finally, lower activity against wild type EGFR


The peak plasma time of drug Tagrisso 80mg is 6 hours

Human plasma protein bound: 95% Volume of distribution: 918L

The main metabolic pathway of drug Tagrisso 80mg
The metabolites are circulating in blood has;

The terminal half life time is 48 hours
Clearance: 14.3 L/hr
The route of excretion of metabolites occur through feces 68% and urine 14% and 2% as unchanged form



Ingredients Osimertinib
Strength 80mg
Pack 30 tablets

Tagrisso available in the strength of; 40mg
80mg Non-small cell lung cancer, metastatic first line (EGFR exon 19 del):
The recommended dose of Tagrisso 80mg is 80mg should be taken as a single dose
It should be administered orally with or without food
Non-small cell lung cancer metastatic previously treated:
80mg should be taken as orally for once a day
Combination with strong CYP3A4 inducers:
Avoid concomitant with strong CYP3A4 inducers
In case of co administration, increase the dose of Tagrisso as 160mg. it should be taken as a single dose
Then decreased the dose of Tagrisso to 80mg 3 weeks after discontinuation of CYP3A4 inducers
If patient is not able to take tablet orally, Tagrisso tablets should be dispersed into 60ml non-carbonated water and drink immediately
In pediatric:
The safety and efficacy of the Tablet Tagrisso 80mg in pediatric patient has not been established
Dosage adjustment:
In pulmonary:
Interstitial lung disease or pneumonitis: permanently discontinue Tagrisso 80mg
QT interval greater than 500 msec on 2 ECGsb: withhold the Tagrisso 80mg until QTc is less than 481 msec then continue the drug as 40mg
In cardiac:
QT prolongation causes life threatening conditions: stop Tagrisso 80mg
Congestive heart failure, asymptomatic left ventricular dysfunction: stop Tagrisso 80mg
If adverse reaction:
Grade 3: stop the drug for 3 weeks
If improvement to Grade 0-2 within 3 weeks: continue at 40mg
No improvement: discontinue the drug

Side effects

Tagrisso 80mg causes;
Lymphopenia, thrombocytopenia, anemia, diarrhea, rash, neutropenia, hypomagnesemia, hyponatremia, dry skin, nail toxicity, fatigue, hypoglycemia, eye disorders, loss of appetite, cough, nausea, stomatitis, constipation, Pruritus, vomiting
Back pain, headache, hypokalemia, Lymphopenia, venous thromboembolism, pneumonia, interstitial lung disease, QT prolongation, neutropenia, hyponatremia, hypomagnesemia, loss of appetite
<1% :
Keratitis, nausea, vomiting, rash, back pain, thrombocytopenia Increased AST, ALT Hyperbilirubinaemia


While taking Tagrisso 40mg, care should be taken to avoid these conditons :
Tagrisso 80mg causes interstitial lung disease in this condition the drug should be permanently discontinued
QT prolongation
Cardiomyopathy, keratitis
Embryo fetal toxicity.
Non-clinical toxicology :
Carcinogenesis, mutagenesis, impairment of fertility
Bone marrow depression like Lymphopenia thrombocytopenia, neutropenia, anemia
Ocular toxicity
Pulmonary toxicity
Fertility effects
Gastrointestinal toxicity.


  • Concomitant of Tagrisso 80mg with CYP3A4 inducers: may cause decreased exposure to Tagrisso 80mg leads to reduce the efficacy
  • CYP3A4 inducers: phenytoin, carbamazepine, Phenobarbital
  • Co administration of Tagrisso 80mg with BCRP: cause increased in exposure to BCRP substrates to increase the toxicity
  • BCRP substrates: rosuvastatin, sulfasalazine, topotecan
  • Some list of drugs :
    BCG vaccine, Bosentan, Chloramphenicol, CYP3A4 inducers, Dabrafenib, Deferiprione, Denosumab, Enzalutamide, QT prolongating agents, promazine, probucol, vaccines, ketaconazole, voriconazole, rifampin, ritonavir


Hypersensitivity reaction occurs while patients are in tolerated to the components present

Tagrisso 80mg causes embryo fetal toxicity, it is not recommended in pregnancy condition

Breast feeding is not recommended

Store at 25°C(77°F)excursions are permitted between 25°C and 30°C (59°F and 86°F).
Keep away from moisture, heat and light

Generally Tagrisso 80mg tablets have serious ill effects, if patient fails to take the dose of Pomalidomide, must consult with well practiced oncologist and get the suggestion
Otherwise the missed dose should be skipped and follow the regular schedule
Pomalid tablet is generally take as once daily per day
Do not double the dose .


Quick Contact

Prescription upload


Blueberrypharma.com , a fully licensed and regulated pharmacy medicine, takes all precautions to strictly abide by the laws and regulations set forth in the dispensing of prescription medications. By placing the order for your prescription medicines, you acknowledge and accept the following terms regarding the purchase of any prescription medicines.

Blueberrypharma.com will not dispense any prescription medication without a valid prescription from a licensed physician.

If you are ordering prescription medication(s), you hereby confirm that you will send us a scanned copy of your valid prescription(s) via email, fax, Whatsapp, or by post, and this prescription shall then be subject to the scrutiny of and approval by our qualified Pharmacists.

The drug information provided in the Blueberrypharma.com is for informative purposes only and this Website is not intended to provide diagnosis, treatment or medical advice. We are not liable for any adverse effects or harm to you as a result of your reliance on the information in the Website.

Blueberrypharma.com requires either the User or Customer or the Caregiver to confirm he/she is completely aware of the indications, side effects, drug interactions, effects of missed dose or overdose of the medicines he/she orders from us. It is imperative to seek professional advice from your physician before purchasing or consuming any medicine from Blueberrypharma.com

At Blueberrypharma.com , a Caregiver can order prescription medicines on your behalf.